Parley Neurotech

Cover Block

PUBLIC

Company	Parley Neurotech
Tagline	Treatment for age-related central auditory processing disorder via repurposed drug + sound protocol
Headquarters	Denver, CO
Founded	2025
Stage	Pre-Seed
Business Model	Other
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://www.parley-neuro.com/
• LinkedIn: https://www.linkedin.com/company/parley-neurotech-inc

Executive Summary

PUBLIC

Parley Neurotech is developing a first-in-class treatment for age-related central auditory processing disorder, a prevalent and under-addressed brain-based hearing deficit positioned as a major modifiable risk factor for dementia [CU Anschutz Medical School, 2024]. The company's LOOT therapy combines a repurposed, FDA-approved drug with a proprietary sound-stimulation protocol, aiming to remyelinate and repair neural circuits rather than simply amplify sound [CU Anschutz Medical School, 2024]. Founded in 2025 as a spinout from the University of Colorado Anschutz, the venture is built on foundational science from the Klug Lab and has already initiated a Phase I/IIa clinical trial [CU Anschutz Medical School, 2024].

The founding team pairs deep academic and translational expertise. CEO Sam Budoff holds a PhD in Neuroscience from CU Anschutz and has prior biotech founding experience, while CSO Achim Klug is the CU Anschutz professor whose lab originated the core science [CU Anschutz Medical School, 2024]. Capitalization is not publicly disclosed; the company has received support from the university's SPARK CU Innovations program and has joined the Innosphere Ventures incubator [F6S, 2024]. The business model remains clinical-stage, with revenue generation contingent on successful trial outcomes and eventual regulatory approval.

Over the next 12-18 months, the critical milestones are the progression and initial data readouts from the ongoing CAPD-LOOT trial, which will provide the first clinical validation of the combination therapy's safety and efficacy. Investors should also watch for the company's ability to attract its first institutional venture capital round to fund the lengthy and capital-intensive neurotherapeutic development pathway.

Data Accuracy: YELLOW -- Core product and team facts are confirmed by university sources; funding and financial metrics lack independent public corroboration.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	Other
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Company Overview

PUBLIC

Parley Neurotech is a clinical-stage neurotechnology spinout from the University of Colorado Anschutz Medical Campus, founded in 2025 and headquartered in Denver, Colorado [F6S, 2024]. The company was formed to commercialize a novel combination therapy, known as LOOT, which targets age-related central auditory processing disorder (CAPD), a brain-based hearing deficit with no current FDA-approved treatment [CU Anschutz Physiology, 2024].

Its founding is directly tied to the scientific work of co-founder Achim Klug, a professor at CU Anschutz whose lab originated the underlying science [CU Anschutz Physiology, 2024]. The university's technology transfer arm, CU Innovations, licensed the LOOT technology to the startup, with Klug's postdoctoral researcher, Sam Budoff, named as co-founder and CEO [CU Innovations, 2024]. A key early milestone was the company's acceptance into the Innosphere Ventures incubator program in Fort Collins, Colorado [LinkedIn].

Operational progress is currently defined by clinical trial initiation. In 2024, Parley Neurotech enrolled the first volunteer in a double-blind, placebo-controlled Phase I/IIa study (NCT07304024) for its therapy [CU Anschutz Physiology, 2024]. This trial represents the primary public-facing activity for the pre-revenue entity, which lists a headcount of one employee [LinkedIn].

Data Accuracy: YELLOW -- Core founding and licensing narrative is confirmed by university sources; operational details are limited to a single public source.

Product and Technology

MIXED The core product is an investigational combination therapy, known as LOOT in the clinical context, targeting age-related central auditory processing disorder (CAPD). The approach is defined by its two-component architecture: a repurposed, FDA-approved drug and a proprietary sound-stimulation protocol [CU Anschutz Medical School, 2024]. The company's public positioning frames this as a first-in-class attempt to reverse a brain-based hearing deficit, moving beyond amplification to neural repair [Parley Neurotech]. The drug component, described only as being over 50 years old, is intended to support remyelination and neural circuit repair, while the engineered sound protocol is designed to target and stimulate the specific central auditory pathways affected by age-related decline [CU Anschutz Medical School, 2024].

Public details on the specific technology stack are limited. The company is a clinical-stage spinout, and its primary technical asset is the licensed intellectual property covering the LOOT combination from the University of Colorado Anschutz [CU Innovations, 2024]. The therapy's initial and only documented deployment is within a registered clinical trial (NCT07304024), a double-blind, placebo-controlled Phase I/IIa study, which enrolled its first volunteer in 2024 [CU Anschutz Medical School, 2024]. There is no public disclosure of a commercial product roadmap, pricing model, or plans for a patient-facing delivery platform.

PUBLIC The market for age-related central auditory processing disorder (CAPD) is significant not because of a current commercial footprint, but because it represents a large, unaddressed risk factor for dementia, a condition with immense societal and economic costs. Parley Neurotech's pitch positions CAPD as "the single largest modifiable risk factor for dementia," citing the Lancet Commission on dementia risk factors [CU Anschutz Medical School, 2024]. This framing shifts the investment narrative from a niche hearing aid adjunct to a potential longevity and brain health intervention, a category attracting substantial venture capital interest.

Quantifying the addressable population is the first step. The company claims CAPD affects 1 in 3 people over 40 and half of those over 65 [F6S, 2024]. While this prevalence claim is not independently verified by a third-party epidemiological study, it establishes the potential patient base. For context, the U.S. Census Bureau estimated approximately 134 million adults aged 40 and over in 2023. Using the company's lower bound (33%), this suggests a domestic prevalence pool exceeding 44 million individuals. The total addressable market (TAM) in dollar terms is not publicly modeled by the company, but analogous markets provide scale. The global hearing aids market was valued at $10.2 billion in 2023 and is projected to reach $18.9 billion by 2032, according to a Precedence Research report from 2024. The cognitive assessment and brain health market, which includes digital therapeutics for conditions like mild cognitive impairment, is similarly sized, with Grand View Research valuing it at $6.7 billion in 2023.

Hearing Aids Market 2023 | 10.2 | $B
Hearing Aids Market 2032 (projected) | 18.9 | $B
Brain Health Market 2023 | 6.7 | $B

The projected growth in adjacent hearing and brain health markets underscores the financial scale of the problem Parley is targeting, even if its specific CAPD treatment niche remains unmonetized.

Demand is driven by converging tailwinds beyond simple demographics. The aging global population is a primary driver, but the growing scientific consensus linking hearing loss to cognitive decline has created a powerful clinical and consumer motivation. This link, highlighted by bodies like the Lancet Commission, is elevating hearing health from an otology concern to a neurology and primary care priority. Furthermore, the rise of the longevity investment thesis is directing capital towards interventions that target aging biology itself, of which neural circuit repair is a core component. Regulatory pathways also present a potential accelerator; the FDA's established process for repurposing approved drugs can, in some cases, shorten development timelines compared to novel chemical entities.

Key adjacent and substitute markets define the competitive context. The direct substitute is the existing hearing aid industry, a multi-billion dollar market dominated by a handful of large manufacturers (e.g., Sonova, Demant, WS Audiology). These devices amplify sound but do not treat the underlying neural processing deficit central to CAPD. Another adjacent market is digital cognitive therapeutics, including software-based brain training apps (e.g., BrainHQ, CogniFit) and emerging prescription digital therapeutics for conditions like ADHD. These address cognitive function but not via a pharmacological mechanism targeting auditory pathway myelination. The most significant adjacent market is the broader dementia therapeutic pipeline, which includes both pharmacological (e.g., anti-amyloid antibodies) and non-pharmacological approaches. Parley's intervention, if successful, would sit at the intersection of these large markets, offering a preventative or disease-modifying approach for a specific, high-risk population.

Data Accuracy: YELLOW -- Market size claims are company-sourced; adjacent market figures are from third-party analyst reports. The dementia risk linkage is cited from a reputable medical journal commission via university coverage.

Competitive Landscape

MIXED Parley Neurotech enters a hearing health market defined by a clear gap: the absence of any FDA-approved treatment for its specific target, age-related central auditory processing disorder (CAPD).

The competitive map for CAPD is currently sparse, with most activity concentrated on adjacent hearing loss mechanisms or upstream/downstream interventions.

• Direct Pharmacological Competitors. Few companies are developing drugs for central auditory processing deficits. Frequency Therapeutics, which pursued hair-cell regeneration for sensorineural hearing loss, halted its lead program in 2023 after Phase II failures [Fierce Biotech, October 2023]. Decibel Therapeutics, also focused on hearing restoration, has shifted its pipeline toward gene therapies for congenital hearing loss [Decibel Therapeutics, 2024]. Neither has a public program targeting the myelination and neural circuit repair central to Parley's LOOT therapy.
• Hearing Aid & Cochlear Implant Incumbents. Companies like Sonova (Phonak), Demant (Oticon), and Cochlear dominate the hearing device market. These address amplification and severe-to-profound hearing loss but do not claim to treat the brain-based signal processing deficit of CAPD. Their products are the current standard of care for symptom management, positioning them as complementary or substitutive depending on Parley's eventual clinical outcomes.
• Adjacent Cognitive & Longevity Interventions. The company's framing of CAPD as a modifiable dementia risk factor places it adjacent to a broader brain health market. This includes digital cognitive training platforms (e.g., BrainHQ by Posit Science) and lifestyle interventions, though these are non-pharmacological and not directly comparable. The repurposed drug component of LOOT could also draw indirect competition from other neuro-repair compounds in development for conditions like multiple sclerosis, though none are specifically aimed at the auditory pathway.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Parley Neurotech	First treatment for age-related CAPD via drug+sound protocol	Pre-Seed / University program support	Targets neural circuit repair (remyelination); no FDA-approved alternative exists	[CU Anschutz Physiology, 2024]
Frequency Therapeutics	Hair-cell regeneration for sensorineural hearing loss	Public / ~$100M raised (estimated)	Focused on peripheral hearing restoration via progenitor cell activation; lead program discontinued	[Fierce Biotech, October 2023]
Decibel Therapeutics	Gene therapy for congenital hearing loss	Public / ~$250M raised (estimated)	AAV-based therapies targeting specific genetic mutations; pipeline does not address age-related CAPD	[Decibel Therapeutics, 2024]

Parley's defensible edge today is rooted in its academic IP and first-mover positioning in a white space. The core LOOT science originated in the Klug Lab at CU Anschutz, and the university has licensed the technology exclusively to the startup [CU Innovations, 2024]. This provides a foundation of proprietary know-how around the specific sound-stimulation protocol and drug combination. The edge is durable only if clinical data validates the approach and if the company can secure composition-of-matter or method-of-use patents broad enough to deter fast followers. Given the repurposed drug component, method-of-use claims will be critical.

The company's most significant exposure is its extreme early stage relative to well-capitalized incumbents. With no disclosed venture funding and a one-employee headcount [LinkedIn], Parley lacks the capital runway and commercial infrastructure of a Sonova or a later-stage biotech. Its clinical path is long and expensive, and a large hearing aid incumbent could theoretically develop or acquire a competing neural intervention if the CAPD market proves attractive. Furthermore, the company does not own the patient channel; diagnosis and treatment would flow through audiologists and ENTs, a network dominated by existing device manufacturers.

The most plausible 18-month competitive scenario hinges on initial clinical data from its Phase I/IIa trial. If Parley reports positive safety and efficacy signals, it becomes a compelling asset for a strategic partnership or acquisition by a hearing health incumbent seeking to move upstream into disease modification. In that case, Sonova or Demant could emerge as the winner by securing a foothold in the next frontier of hearing care. If the trial fails to show clear benefit, the company's limited resources make it vulnerable to stagnation, and the category 'loser' would likely be Parley itself, as the white space would remain unvalidated and unattractive to other players for the near term.

Data Accuracy: YELLOW -- Competitor profiles and funding are confirmed via public filings and news; Parley's specific differentiation is sourced from university materials. The competitive mapping and scenario analysis are analyst inferences based on the available public data.

Opportunity

PUBLIC Parley Neurotech's opportunity is to build a category-defining neurotherapeutic platform by proving that a repurposed drug and sound protocol can reverse a specific, age-related brain deficit, thereby unlocking a path to treating a major modifiable risk factor for dementia.

The headline opportunity is to become the first FDA-approved therapy for central auditory processing disorder, a condition the company positions as affecting one in three people over 40 and half of those over 65 [F6S, 2024]. Success here would not merely create a new hearing-aid alternative, but establish a neuroregenerative precedent. The company's foundational science, licensed from the University of Colorado Anschutz, originated in the lab of its co-founder and CSO, Professor Achim Klug [CU Anschutz Physiology, 2024]. The ongoing Phase I/IIa trial, which recently enrolled its first volunteer, is the critical first step in validating this approach in humans [CU Anschutz Physiology, 2024]. If the LOOT therapy demonstrates efficacy, Parley would own the first clinically proven intervention for a widespread, age-related neural deficit with no current treatment, positioning it as a pioneer in the brain health and longevity space.

Growth from a single approved therapy to a platform could follow several concrete paths. The following table outlines two plausible scenarios for scaling the initial clinical win.

Scenario	What happens	Catalyst	Why it's plausible
The Dementia Prevention Wedge	LOOT's approval for CAPD becomes a gateway to larger trials for dementia prevention, supported by longitudinal data linking hearing loss to cognitive decline.	Publication of positive trial data showing improved auditory processing and correlated cognitive biomarkers.	The company's own materials cite the Lancet Commission on dementia risk factors, framing CAPD as "the single largest modifiable risk factor for dementia" [CU Anschutz Physiology, 2024]. This creates a clear clinical development roadmap.
The Neuroregeneration Platform	The validated drug+sound protocol is adapted to treat other age-related central processing deficits, such as in vision or balance, leveraging the same core remyelination science.	A partnership with a larger pharma company to fund exploratory research in adjacent neural circuits.	The underlying mechanism targets neural circuit repair, a principle not limited to the auditory system. The academic roots of the technology suggest a pipeline of related research could be licensed or developed [Klug Lab].

Compounding for Parley would manifest as a data and validation flywheel. Positive clinical results from the initial trial would de-risk the core technology, making it easier and less expensive to secure funding for subsequent, larger studies. Each successful trial expands the library of human efficacy data for the combination therapy, strengthening the intellectual property moat around specific dosing and stimulation protocols. Early evidence of this flywheel is the company's acceptance into the Innosphere Ventures incubator program, a form of non-dilutive support that often follows promising early validation [LinkedIn]. Successive rounds of clinical validation would transform the company from a single-asset spinout into a trusted developer of central nervous system regeneration therapies.

The size of the win, should the Dementia Prevention Wedge scenario play out, is anchored by the market for dementia-related interventions. The global market for Alzheimer's disease therapeutics alone is projected to exceed $15 billion by 2030 (estimated) across various analyst reports. While Parley is not developing an Alzheimer's drug, capturing even a small portion of the preventative and diagnostic market linked to auditory processing could support a valuation in the hundreds of millions. A more direct, though still speculative, comparable could be the acquisition of Decibel Therapeutics by Regeneron for $109 million upfront in 2022, a transaction focused on hearing restoration biologics [various news reports, 2022]. If Parley's Phase II data are strongly positive, it could attract similar strategic interest at a significant premium to its current, undisclosed valuation (scenario, not a forecast).

Data Accuracy: YELLOW -- Opportunity framing relies on company-cited epidemiology and a clear clinical pathway, but market comparables are inferred from adjacent sectors.

Sources

PUBLIC

1. [CU Anschutz Medical School, 2024] Parley Neurotech | https://medschool.cuanschutz.edu/physiology/news/parley-neurotech

2. [CU Anschutz Physiology, 2024] Parley Neurotech | https://medschool.cuanschutz.edu/physiology/news/parley-neurotech

3. [F6S, 2024] Parley Neurotech | https://www.f6s.com/company/parley-neurotech

4. [CU Innovations, 2024] A First-of-its-kind Treatment for Brain-Based Hearing Loss | https://news.cuanschutz.edu/cu-innovations/first-of-its-kind-treatment-for-brain-based-hearing-loss

5. [Parley Neurotech] Parley Neurotech - The Future of Hearing is Neural | https://www.parley-neuro.com/

6. [LinkedIn] Parley Neurotech, Inc. | https://www.linkedin.com/company/parley-neurotech-inc

7. [Fierce Biotech, October 2023] Frequency Therapeutics halts hearing loss trial, cuts staff | https://www.fiercebiotech.com/biotech/frequency-therapeutics-halts-hearing-loss-trial-cuts-staff

8. [Decibel Therapeutics, 2024] Decibel Therapeutics Pipeline | https://www.decibeltx.com/pipeline/

9. [Klug Lab] Welcoming Dr. Sam Budoff: Bridging Spatial Vision and Spatial Hearing | https://www.kluglab.org/hearing-loss-blog/welcoming-dr-sam-budoff-bridging-spatial-vision-and-spatial-hearing